2371-35-9

Usage

Uses

Used in Pharmaceutical Industry:
2-[(3-methylphenyl)amino]acetohydrazide is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of potential drugs.
Used in Anticancer Applications:
2-[(3-methylphenyl)amino]acetohydrazide is used as a potential anticancer agent due to its demonstrated ability to inhibit the growth of cancer cells, making it a candidate for further research and development in oncology.
Used in Antibacterial Applications:
2-[(3-methylphenyl)amino]acetohydrazide is used as a potential antibacterial agent, given its investigated properties against bacterial strains, which could lead to its use in the development of new antibiotics.
Used in Antifungal Applications:
2-[(3-methylphenyl)amino]acetohydrazide is used as a potential antifungal agent, with studies indicating its possible effectiveness against fungal infections, warranting further exploration for use in antifungal medications.

InChI:InChI=1/C9H13N3O/c1-7-3-2-4-8(5-7)11-6-9(13)12-10/h2-5,11H,6,10H2,1H3,(H,12,13)

Upstream product

• 126689-79-0 methyl 2-(m-tolylamino)acetate 
• 108-44-1 1-amino-3-methylbenzene 
• 21911-66-0 N-(3-methylphenyl)glycine ethyl ester 

Downstream Products

• 1463964-86-4 N'-benzyl 2-(m-tolylamino)acetohydrazide 

Relevant academic research and scientific papers

CATHEPSIN-D AND ANGIOGENESIS INHIBITORS AND COMPOSITIONS THEREOF FOR TREATING BREAST CANCER

The invention relates to Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer. More particularly, the invention relates to the design and synthesis of inhibitors of Cathepsin D which exhibits antiproliferative activity and also inhibits angiogenesis. The present invention also relates to the compositions thereof for treating breast cancer.

Novel TypeII Fatty Acid Biosynthesis (FAS II) Inhibitors as Multistage Antimalarial Agents

Malaria is a potentially fatal disease caused by Plasmodium parasites and poses a major medical risk in large parts of the world. The development of new, affordable antimalarial drugs is of vital importance as there are increasing reports of resistance to the currently available therapeutics. In addition, most of the current drugs used for chemoprophylaxis merely act on parasites already replicating in the blood. At this point, a patient might already be suffering from the symptoms associated with the disease and could additionally be infectious to an Anopheles mosquito. These insects act as a vector, subsequently spreading the disease to other humans. In order to cure not only malaria but prevent transmission as well, a drug must target both the blood- and pre-erythrocytic liver stages of the parasite. P.falciparum (Pf) enoyl acyl carrier protein (ACP) reductase (ENR) is a key enzyme of plasmodial typeII fatty acid biosynthesis (FASII). It has been shown to be essential for liver-stage development of Plasmodium berghei and is therefore qualified as a target for true causal chemoprophylaxis. Using virtual screening based on two crystal structures of PfENR, we identified a structurally novel class of FAS inhibitors. Subsequent chemical optimization yielded two compounds that are effective against multiple stages of the malaria parasite. These two most promising derivatives were found to inhibit blood-stage parasite growth with IC50 values of 1.7 and 3.0μM and lead to a more prominent developmental attenuation of liver-stage parasites than the gold-standard drug, primaquine.